As a researcher committed to finding better treatments for cancer, my work tackles one of the  most stubborn problems: why do patients who initially respond well to cancer drugs eventually stop responding? In melanoma, this happens to roughly half of all patients within just six to eight months. The reason is that not all cancer cells are the same. Within a single tumor, some cells are vulnerable to treatment while others are resistant, hiding in plain sight and waiting to take over once the sensitive cells are destroyed. Current therapies are simply not equipped to target both groups at once, leaving patients with fewer options.

In this project, we are building tiny, intelligent drug carriers made of porous silica that can co-load vemurafenib and metformin, and release them only inside the tumor, triggered by the tumor's own hostile chemistry. These carriers are capped with natural polyphenols. The polyphenols act as molecular gatekeepers which are locked under normal conditions, but opened by the abnormalities in resistant tumor microenvironment. Once unlocked, the first drug targets the fast-growing cancer cells, the while second dismantles the metabolic survival strategy of resistant ones. Furthermore, the released plant compounds themselves join the fight and push the resistant cells toward multiple cell death pathways at once.

To validate these effects in a living system, zebrafish will serve as the preclinical platform. Zebrafish can be genetically engineered to grow human-like melanoma tumors, allowing us to directly observe how the nanoparticles behave inside a real tumor.

By weaving together materials science, pharmacology, and preclinical modelling in zebrafish, this project represents a multidisciplinary vision of what future cancer therapy could look like: not a single drug fighting a single target, but an adaptive, intelligent platform that outwits tumors on their own terms.